<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>379</serviceExecutionTime><Drug id="31211"><DrugName>FBPase inhibitors, Ontogen</DrugName><DrugSynonyms><Name><Value>FBPase inhibitors, Ontogen</Value></Name></DrugSynonyms><CompanyOriginator id="22709">Ontogen Corp</CompanyOriginator><CompaniesSecondary><Company id="22709">Ontogen Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22709" type="Company"><TargetEntity id="4296345305" type="organizationId">Ontogen Corp</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="7678" type="Action"><TargetEntity id="3122" type="Mechanism">Fructose 1,6-Biphosphate Aldolase Inhibitor</TargetEntity><TargetEntity id="1344" type="Mechanism">Fructose-1,6-Bisphosphatase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00768" type="ciTarget"><TargetEntity id="60907871022033" type="siTarget">Fructose-1,6-bisphosphatase 1</TargetEntity><TargetEntity id="8177" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="7678">Fructose 1,6 biphosphatase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-24T10:00:12.000Z</LastModificationDate><ChangeDateLast>2008-10-08T12:46:58.000Z</ChangeDateLast><AddedDate>2000-10-23T13:28:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22709" linkType="Company"&gt;Ontogen Corp&lt;/ulink&gt; was investigating a series of selective, non-peptide, non-carbohydrate, non-nucleoside, small molecule inhibitors of fructose-1,6-bis-phosphatase (FBPase) for the potential treatment of type 2 diabetes. Lead optimization  in animal models was underway by October 2000 [&lt;ulink linkID="386501" linkType="reference"&gt;386501&lt;/ulink&gt;], [&lt;ulink linkID="386502" linkType="reference"&gt;386502&lt;/ulink&gt;], and was ongoing in July 2002 [&lt;ulink linkID="457902" linkType="reference"&gt;457902&lt;/ulink&gt;]; however, by May 2006, Ontogen had forfeited its rights to trade and  all research and development activities were presumed to be  discontinued [&lt;ulink linkID="933319" linkType="Reference"&gt;933319&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;These inhibitors appeared to recognize an accessory site on FBPase which lead to the reversible inhibition of the enzyme [&lt;ulink linkID="386502" linkType="reference"&gt;386502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2002, Ontogen was awarded a $1.3 million Phase II SBIR grant from the NIH to aid in the development of these enzyme inhibitors. The research covered by the phase II grant was to begin immediately [&lt;ulink linkID="435168" linkType="reference"&gt;435168&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-05-26T00:00:00.000Z</StatusDate><Source id="933319" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22709">Ontogen Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-23T00:00:00.000Z</StatusDate><Source id="386501" type="CONFERENCE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00768"><Name>Fructose 1,6 biphosphatase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22709">Ontogen Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116744" title="NIAID to award grant to Ontogen for development of FBPase inhibitors against type II diabetes    "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>